Literature DB >> 15023324

[Should the menopause be treated?].

E Bailón1.   

Abstract

Mesh：

Year:  2004        PMID： 15023324      PMCID： PMC7668954          DOI： 10.1016/s0212-6567(04)79395-6

Source DB:  PubMed          Journal:  Aten Primaria        ISSN： 0212-6567            Impact factor:   1.137


× No keyword cloud information.
  35 in total

Review 1.  Menopause: its epidemiology and potential association with chronic diseases.

Authors:  M R Sowers; M T La Pietra
Journal:  Epidemiol Rev       Date:  1995       Impact factor: 6.222

Review 2.  Hormone replacement therapy.

Authors:  E Barrett-Connor
Journal:  BMJ       Date:  1998-08-15

3.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.

Authors: 
Journal:  Lancet       Date:  1997-10-11       Impact factor: 79.321

4.  The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind placebo-controlled trial.

Authors:  S Jackson; A Shepherd; S Brookes; P Abrams
Journal:  Br J Obstet Gynaecol       Date:  1999-07

5.  Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.

Authors:  J A Cauley; L Norton; M E Lippman; S Eckert; K A Krueger; D W Purdie; J Farrerons; A Karasik; D Mellstrom; K W Ng; J J Stepan; T J Powles; M Morrow; A Costa; S L Silfen; E L Walls; H Schmitt; D B Muchmore; V C Jordan; L G Ste-Marie
Journal:  Breast Cancer Res Treat       Date:  2001-01       Impact factor: 4.872

6.  Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.

Authors:  I Persson; J Yuen; L Bergkvist; C Schairer
Journal:  Int J Cancer       Date:  1996-07-29       Impact factor: 7.396

7.  Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.

Authors:  Tomas Riman; Paul W Dickman; Staffan Nilsson; Nestor Correia; Hans Nordlinder; Cecilia M Magnusson; Elisabete Weiderpass; Ingemar R Persson
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

8.  Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.

Authors:  Garnet L Anderson; Howard L Judd; Andrew M Kaunitz; David H Barad; Shirley A A Beresford; Mary Pettinger; James Liu; S Gene McNeeley; Ana Maria Lopez
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

9.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

Review 10.  Hormones and depression: what are the facts about premenstrual syndrome, menopause, and hormone replacement therapy?

Authors:  T B Pearlstein
Journal:  Am J Obstet Gynecol       Date:  1995-08       Impact factor: 8.661
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.